[1] S. NUGENT. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs[J]. Gut, 2001, 48 1: 571-577. DOI:
10.1136/gut.48.4.571[2] R. PAMUKCU E C S Hanauer. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.[J]. Gastroenterology, 1988, 95 4 1: 975-981. DOI:
10.5555/uri:pii:0016508588901722[3] A Q MOHSEN. Effects of olsalazine in the jejunum of the rat.[J]. Gut, 1987, 28 3: 346-352. DOI:
10.1136/gut.28.3.346[4] S MURTHY. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis.[J]. Inflammation Research, 1997, 46 6: 224-233. DOI:
10.1007/s000110050177[5] YANFEN NIU . Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity[J]. Journal of pharmacological sciences, 2017, 135 3: Pages 114-120. DOI:
10.1016/j.jphs.2017.10.007